首页> 外文期刊>BMC Infectious Diseases >Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis
【24h】

Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis

机译:埃塞俄比亚地区的多药耐药性结核病及其与以前抗结核病治疗史的关联:系统评价和荟萃分析

获取原文

摘要

Background Efforts to control the global burden of tuberculosis (TB) have been jeopardized by the rapid evolution of multi-drug resistant Mycobacterium tuberculosis (MTB), which is resistant to at least isoniazid and rifampicin. Previous studies have documented variable prevalences of multidrug-resistant tuberculosis (MDR-TB) and its risk factors in Ethiopia. Therefore, this meta-analysis is aimed, firstly, to determine the pooled prevalence of MDR-TB among newly diagnosed and previously treated TB cases, and secondly, to measure the association between MDR-TB and a history of previous anti-TB drugs treatment. Methods PubMed, Embase and Google Scholar databases were searched. Studies that reported a prevalence of MDR-TB among new and previously treated TB patients were selected. Studies or surveys conducted at national or sub-national level, with reported MDR-TB prevalence or sufficient data to calculate prevalence were considered for the analysis. Two authors searched and reviewed the studies for eligibility and extracted the data in pre-defined forms. Forest plots of all prevalence estimates were performed and summary estimates were also calculated using random effects models. Associations between previous TB treatment and MDR-MTB infection were examined through subgroup analyses stratified by new and previously treated patients. Results We identified 16 suitable studies and found an overall prevalence of MDR-TB among newly diagnosed and previously treated TB patients to be 2% (95% CI 1% - 2%) and 15% (95% CI 12% - 17%), respectively. The observed difference was statistically significant ( P Conclusions The burden of MDR-TB remains high in Ethiopian settings, especially in previously treated TB cases. Previous TB treatment was the most powerful predictor for MDR-MTB infection. Strict compliance with anti-TB regimens and improving case detection rate are the necessary steps to tackle the problem in Ethiopia.
机译:背景技术对多药耐药性结核分枝杆菌(MTB)的快速发展已经危害了控制全球结核病(TB)的工作,而结核分枝杆菌至少对异烟肼和利福平具有耐药性。先前的研究已经记录了埃塞俄比亚耐多药结核病(MDR-TB)的流行率及其危险因素。因此,这种荟萃分析的目的是,首先确定新诊断和先前治疗的结核病患者中耐多药结核病的合并患病率,其次,测量耐多药结核病与以前抗结核药物治疗史之间的关联。方法搜索PubMed,Embase和Google Scholar数据库。选择报告新的和先前治疗的结核病患者中MDR-TB患病率高的研究。在分析中考虑了在国家或国家以下各级进行的研究或调查,其报告的耐多药结核病患病率或足以计算患病率的数据。两位作者搜索并审查了研究的资格,并以预定义的形式提取了数据。执行所有流行度估计值的森林图,并使用随机效应模型计算汇总估计值。通过对新患者和先前治疗的患者进行分层的亚组分析,检查了先前的结核病治疗与MDR-MTB感染之间的关联。结果我们确定了16项合适的研究,发现新诊断和先前治疗的TB患者的MDR-TB总体患病率分别为2%(95%CI 1%-2%)和15%(95%CI 12%-17%) , 分别。观察到的差异具有统计学意义(P结论埃塞俄比亚地区的耐多药结核病负担仍然很高,尤其是在先前治疗过的结核病病例中。以前的结核病治疗是耐多药MTB感染的最有力预测指标。提高案件发现率是解决埃塞俄比亚问题的必要步骤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号